You searched for "Glaucoma UK"

1036 results found

The structure function relationship in glaucoma

Chronic open angle glaucoma (COAG) is the second most common cause of blindness worldwide. It is diagnosed on the basis of three clinical signs, raised intraocular pressure (IOP), visual field (VF) defects and structural changes to the optic nerve head...

Corneal hysteresis: An emerging biomarker in the management of glaucoma

Corneal hysteresis (CH) is gaining recognition as a valuable parameter in the management of glaucoma. Corneal hysteresis is defined as the difference between the inward and outward pressure responses of the cornea during deformation. This measurement reflects the viscoelastic properties...

Glaucoma Awareness Week 26

Glaucoma Awareness Week is an annual awareness-raising opportunity where we encourage people across the UK to talk about glaucoma. Over 700,000 people in the UK have glaucoma. Half of them don’t know they have it. Glaucoma UK want to end...

Report: UKEGS 2024

It was an incredible experience heading down to UKEGS 2024 earlier this month in Southampton. The entire Glaucoma UK team, along with the UKEGS overseeing panel Nishani Amerasinghe, Andrew Tatham, Professir Anthony King and Professor Gus Gazzard, took great care...

Mitomycin C versus 5-FU as an adjunctive treatment for trabeculectomy

Antifibrotic agents are used during trabeculectomy (TRAB) to improve long-term surgical success by reducing fibrosis of subconjunctival and episcleral tissue. The purpose of this meta-analysis was to directly compare the efficacy and safety of the two most frequently used antifibrotic...

Cutting-edge practice in glaucoma care: what, how and why?

More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...

A semi-automated algorithm for identifying glaucoma patients with blindness

Patients with sight impairment (previously referred to as partial sightedness) or severe sight impairment (previously referred to as blindness) are eligible for a certificate of visual impairment (CVI). Certification confers eligibility for a wide range of benefits administered by local...

Atlas of Glaucoma Third edition

Glaucoma patients constitute a significant proportion of any ophthalmology clinic. Hence, a basic understanding, evaluation and management of the condition form part of the essential clinical skillset of any ophthalmologist. Atlas of Glaucoma is a good read and very useful...

Contemporary glaucoma therapy: spoilt for choice

The goal of glaucoma management is to prevent visual loss and disease progression in the patient’s lifetime through effective lowering of intraocular pressure (IOP), the primary modifiable risk factor in glaucoma. Sustained and consistent IOP reduction is key to halting...

The science of glaucoma management: highlights of the 2020 Moorfields International Glaucoma Symposium

Held earlier this year, the 12th annual Moorfields International Glaucoma Symposium provided a forum for advanced clinical and scientific exchange in glaucoma management. The authors describe the key presentation themes and debates, highlighting specific topics of interest to glaucoma specialists....

Severe conjunctival cicatrisation secondary to chronic glaucoma therapy

The timing of glaucoma filteration surgery during the course of chronic progressive glaucoma remains a contentious issue amongst glaucoma specialists. The vast majority support the use of maximal medical treatment initially to achieve the target pressure. Surgical procedures are only...

Beliefs and adherence to glaucoma treatment

The aim of the study was to determine adherence rates and beliefs about glaucoma and its treatment in white Americans, African Americans, white Australians and Singaporeans of Chinese descent. A cross-sectional study of 475 glaucoma patients using topical eye drops...